O. Ringdén

Transplantation · 2003–2015

A researcher in the Science corpus: 8 papers; trusts 0 researchers and is trusted by 3 researchers here, as inferred from the citation graph.

Who trusts O. Ringdén overall

1. A. Caplan
2. M. Lalu

Papers from O. Ringdén's perspective

Ordered by how strongly the researchers O. Ringdén trusts endorse each paper. Same corpus, a different order for every researcher.

1. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. (Experimental Hematology)
2. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone (Proceedings of the National Academy of Sciences of the United States of America)
3. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation (Transplantation)
4. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. (Journal of Clinical Oncology)
5. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH) (Bone Marrow Transplantation)
6. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. (Experimental Hematology)
7. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. (Blood)
8. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants (Science)
9. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. (Journal of Biomedical Sciences)
10. Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex (Scandinavian Journal of Immunology)

Their papers

• Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. (2015) — 624 citations
• Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice (2014) — 283 citations
• Immunomodulation by mesenchymal stem cells and clinical experience (2007) — 692 citations
• Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease (2006) — 1,134 citations
• Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. (2004) — 2,696 citations
• Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells (2003) — 659 citations
• HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. (2003) — 1,734 citations
• Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex (2003) — 1,383 citations